Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Published Date: 04 Oct 2026

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Read Full News

Latest News

Where Does Ameluz PDT Fit Alongside Mohs Surgery? Neal Bhatia, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

7 Dermatology Headlines You Missed in September 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

What the FDA's Approval of Ameluz PDT Means for Skin Cancer Neal Bhatia, MD

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know Victoria Johnson

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

FDA News Recap: Novel Drug Approvals in Q3 2026

Todays Updates

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Todays Updates

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Latest News

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

News All Time

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients Tim Smith

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Competition, Burnout, and the Cost of Always Saying 'Yes' as a Clinician Adam Friedman, MD, FAAD

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

Tips on Saying 'No' as a Dermatology Leader, With Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, discusses saying no strategically as a career skill in a LEADderm 2026 table talk on managing opportunities.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD Lisa A. Swanson, MD

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today Lisa A. Swanson, MD

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

6 Dermatology Headlines You Missed in August 2026 Tim Smith

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Skin Angels and the Atopic Dermatitis Pipeline, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.

Reaching Patients Online and Avoiding Burnout, With Steven Daveluy, MD Steven Daveluy, MD, FAAD

Steven Daveluy, MD, speaks on why dermatologists belong on social media, avoiding burnout in practice, and what excites him in HS treatment.

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD Manju Dawkins, MD

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

KT-621 Achieves Deep STAT6 Degradation, Initial Respiratory, Skin Gains Victoria Johnson

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Dermatology's Path From Idea to Innovation, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know Tim Smith

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

Q&A: Why Saying 'No' is a Career Skill as a Clinician, with Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.

Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer Tim Smith

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

Recommended News For You

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

Colon cancer and exercise: Can physical activity reprogram genes?

Month-Long Wait Times Caused by US Physician Shortage.

Resection for Early Liver Cancer Tied to Improved Survival.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

Recommended Articles For You

Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective 

Immune Remodeling of the Bone-Marrow Niche: Mechanisms, Clinical Implications, and Emerging Therapies 

Targeting Bone Marrow Immune Niches in Refractory Hematologic Disorders 

Know About Lymphangioma: Symptoms, Causes, and Treatments 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy

2.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

3.

In early dementia, SSRIs enhance cognition and major depression.

4.

Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.

5.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

1.

Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions

2.

Teaching Oncologic Emergencies Through Priority-Based Learning

3.

Understanding Protein C Deficiency: Symptoms, Causes, and Treatment

4.

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies

5.

Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

How Advances in Cancer Research Are Improving Treatment Options

2.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

4.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot